Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > September 4, 2020
Daily News
September 4, 2020
- PMDA Presents Views on Efficacy, Safety Evaluations for Domestic Development of COVID-19 Vaccines
September 4, 2020
- Blackstone Setting Sights on IPO of Takeda Consumer Healthcare Within 5-10 Years
September 4, 2020
- Govt Holds 1st Meeting of Regenerative Medicine/Cell Therapy Panel, Eyeing Proposals in FY2021
September 4, 2020
- Kyowa Kirin/Sandoz’s Rituxan Biosimilar Approved for Chronic Idiopathic Thrombocytopenic Purpura
September 4, 2020
- US Launch of Takeda’s Entyvio SC to Be Pushed Back to 2022
September 4, 2020
- Flawed Testing at Kyowa CritiCare Costs 2 More Product Recalls
September 4, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…